Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30866414 | 1.00 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5856065 | 1.00 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5857051 | 0.99 | PPARA (0.98) | PPARAPPARG | |
| SCHEMBL5995415 | 0.93 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5856320 | 0.93 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5856233 | 0.92 | PPARA (0.85) | PPARAPPARG | |
| SCHEMBL5857214 | 0.92 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5857586 | 0.92 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5855510 | 0.91 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5856048 | 0.91 | PPARA (0.83) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2007096261-A2 | PROCESS FOR THE PREPARATION OF DIOXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | claimed |
| US-20070027198-A1 | Crystal of heterocyclic compound | OKADAI TAKESHI | 2007-02-01 | — | — | US | claimed |
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | claimed |
| EP-1666479-A1 | CRYSTAL OF HETEROCYCLIC COMPOUND | Nippon Shinyaku Co., Ltd. (JP) | 2006-06-07 | — | — | EP | claimed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | claimed |
| US-20260128170-A1 | BIOMOLECULAR DETECTION METHOD AND DETECTION SYSTEM THEREOF | UNIV NAT CHENG KUNG (TW) | 2026-05-07 | — | — | US | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250346646-A1 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | disclosed |
| US-12455245-B2 | Cancer diagnosis using raman signal of urine | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2025-10-28 | — | — | US | disclosed |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2005026160-A1 | CRYSTAL OF HETEROCYCLIC COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2005-03-24 | — | — | WO | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | PPARA 464/4885PPARG 393/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | PPARA 579/4885PPARG 603/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | PPARA 660/4885PPARG 701/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | PPARA 660/4885PPARG 701/4885 |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | PPARA 31/4885PPARG 74/4885 |
| US-20260128170-A1 | BIOMOLECULAR DETECTION METHOD AND DETECTION SYSTEM THEREOF | LGALS3, HAVCR2, ALB | PPARA 3593/4885PPARG 4193/4885 |
| US-20070027198-A1 | Crystal of heterocyclic compound | GPR119, ACACA, HMGCR | PPARA 260/4885PPARG 436/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | PPARA 787/4885PPARG 567/4885 |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | PPARA 31/4885PPARG 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.